The Target-Derm registry evaluates adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs).
It will begin by focusing on patients with atopic dermatitis and then expand to include other skin conditions, such as hidradenitis suppurativa, alopecia areata, and vitiligo.
Matt Casbon, chief business officer, of Target PharmaSolutions, told us that using the longitudinal cohort design will “enable characterization of IMISC disease activity and comorbid medical conditions over time, and will cultivate a foundation for more targeted investigations.”
Novartis will join the Target-Derm community as a member of the advisory committee, part of Target PharmaSolution’s model. Novartis will weigh in on the data analysis and research insight, as well as providing financial support.
Longitudinal RWD
Target-Derm is the sixth disease category real-world study Target PharmaSolutions has taken on since 2015. It has ongoing studies in nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV).
A spokesperson for Novartis told us that the company is already a partner on the Target-NASH study and has seen the possibilities of what this type of study can provide at multiple stages of drug development.
“This information [collected from the registry] will inform our drug development and in the end help our ambitions to reimagine the lives of patients who are waiting for innovation in immune-dermatology,” the Novartis spokesperson continued.
Target-Derm will be conducted Using Target PharmaSolution’s standardized model. Using this model, “[Target PharmaSolutions] organizes stakeholders through a turn-key, multidisciplinary approach that includes pharmaceutical partners, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate regulatory grade, longitudinal, real-world clinical data,” said Casbon.
